Topics

Latest "Constance Therapeutics" News Stories

15:02 EST 20th February 2020 | BioPortfolio

Here are the most relevant search results for "Constance Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Constance Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Constance Therapeutics for you to read. Along with our medical data and news we also list Constance Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Constance Therapeutics Companies for you to search.

Showing "Constance Therapeutics" News Articles 1–25 of 8,000+

Relevant

CRISPR Therapeutics Takes Over Joint Venture Casebia Therapeutics from Bayer

LEVERKUSEN, Germany and ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ — CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics. Upon closing of the transaction, Casebia Therapeutics would focus on the development of it...


Proteon Therapeutics to merge with ArTara Therapeutics

Proteon Therapeutics, which focuses on kidney and vascular diseases, has signed a definitive agreement to merge with rare and speciality...Read More... The post Proteon Therapeutics to merge with ArTara Therapeutics appeared first on Pharmaceutical Technology.

Clover Therapeutics Launches With Eye on Age-Related Ocular Diseases

Clover Therapeutics, which sprung out of Clover Health, is supported by a number of biotech and pharma veterans, including Pfizer veteran Cheng Zhang, who is heading up therapeutics, and Genentech veteran Marcel van der Brug, who is the chief scientific officer for therapeutics.


DGAP-Stimmrechte: Vivoryon Therapeutics AG (deutsch)

Vivoryon Therapeutics AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung DGAP Stimmrechtsmitteilung: Vivoryon Therapeutics AG Vivoryon Therapeutics AG: Veröffentl...

iCo Therapeutics Announces Dosing of First Full Cohort in Second Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd.,...

iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities

Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its Australian subsidiary, iCo Therapeutics Pty Ltd....

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics startet Notierung an Frankfurter Börse

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics startet Notierung an Frankfurter Börse Vancouver (Kanada), 13. August 2019. XPhyto Therapeutics Corp. (CSE: XPHY) (XPhyto oder das Unterne...

iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd....

Galera Therapeutics advances on plans for $86M IPO launch

A developer of therapeutics that could revolutionize cancer radiotherapy, Galera Therapeutics has submitted a preliminary pro -More- 

iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects

Vancouver, British Columbia--(Newsfile Corp. - December 24, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd....

RNA Therapeutics Conference and Focus Day

19 - 20 February 2020, London, UK. The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Probably Relevant

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics unterzeichnet Termsheet für deutschen Cannabisvertrieb

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics unterzeichnet Termsheet für deutschen Cannabisvertrieb Vancouver, Kanada (4. November 2019) - XPhyto Therapeutics Corp. (CSE:XPHY; FWB:4XT...

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies' Respective Cell Therapy Programs in Oncology

- CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologo...

XPhyto Therapeutics Corp.: XPhyto Therapeutics Closes Acquisition Of Vektor Pharma TF GmbH

VANCOUVER, CANADA / ACCESSWIRE / September 17, 2019 / XPhyto Therapeutics Corp. (CSE:XPHY)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has closed both the definitive share ...

Adhera Therapeutics, Inc.: Adhera Therapeutics and Indegene Announce Next Gen Commercialization Partnership

RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 10, 2019 / Adhera Therapeutics, Inc. (OTCQB:ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics schließt Übernahme von Vektor Pharma TF GmbH ab

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics schließt Übernahme von Vektor Pharma TF GmbH ab Vancouver, Kanada (17. September 2019). XPhyto Therapeutics Corp. (CSE:XPHY; FWB:4XT) (XPh...

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics engagiert globalen Cannabisexperten für deutsches Geschäft

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics engagiert globalen Cannabisexperten für deutsches Geschäft Vancouver (Kanada), 19. September 2019. XPhyto Therapeutics Corp. (CSE: XPHY, F...

Abeona Therapeutics Inc.: Abeona Therapeutics kündigt öffentliches Angebot von Stammaktien und vorfinanzierten Optionsscheinen an

NEW YORK und CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein voll integriertes führendes Unternehmen im Bereich Gen- und Zelltherapien, gab heute bekannt, ...

Abeona Therapeutics Inc.: Abeona Therapeutics gibt Strategieüberprüfung bekannt

Das Unternehmen engagiert Jefferies LLC als Reaktion auf strategische Inbound-InteressenNEW YORK und CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein volls...

Ryvu Therapeutics (RVU) - Introducing Ryvu Therapeutics

Edison Investment Research - Pharmaceuticals & healthcare - Ryvu Therapeutics: The corporate split is now complete and Selvita is continuing as Ryvu Therapeutics, which will focus on innovative drug development. The contract research organisation (CRO) business, which was spun out, has retained the Selvita brand and is also trading on the Warsaw Stock Exchange. Pawel Przewiezlikowski, co-founder a...

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics nimmt pharmazeutisches Labor für die Cannabisextraktion in Betrieb

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics nimmt pharmazeutisches Labor für die Cannabisextraktion in Betrieb Vancouver, Kanada (25. November 2019) - XPhyto Therapeutics Corp. (CSE:...

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics meldet Übernahme eines deutschen Betäubungs-Spezialisten

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics meldet Übernahme eines deutschen Betäubungs-Spezialisten Vancouver, Kanada (26. August 2019) - XPhyto Therapeutics Corp. (CSE:XPHY; FWB:4X...

Abeona Therapeutics Inc.: Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants

NEW YORK and CLEVELAND, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and s...

Abeona Therapeutics Inc.: Abeona Therapeutics gibt Teilnahme am ersten World Congress on Epidermolysis Bullosa bekannt

NEW YORK und CLEVELAND, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), ein voll integriertes führendes Unternehmen im Bereich Gen- und Zelltherapie, gab heute seine Teil...

Atlantic Therapeutics secures FDA approval for OTC use of INNOVO

Atlantic Therapeutics, a provider of medical therapeutics, has secured the US Food and Drug Administration (FDA) over-the-counter (OTC) approval of its INNOVO, intended for stress urinary incontinence (SUI). The post Atlantic Therapeutics secures FDA approval for OTC use of INNOVO appeared first on NS Medical Devices.


Quick Search

News Quicklinks